5 Biggest Immunotherapy Companies in the World

1. Johnson & Johnson (NYSE:JNJ)

Market Capitalization: $515.34 billion

Number of Hedge Fund Holders: 84

Johnson & Johnson (NYSE:JNJ) is a New Brunswick, New Jersey-based global pharmaceutical corporation. The company’s key checkpoint inhibitor is called ciltacabtagene autoleucel (cilta-cel), which is a CAR-T cell therapy created for the treatment of multiple myeloma. The corporation is also involved in the development of immunotherapies for other diseases, including autoimmune diseases and inflammatory disorders. Johnson & Johnson (NYSE:JNJ) has also developed a drug called ustekinumab, which is a monoclonal antibody used to treat autoimmune diseases like psoriasis and Crohn’s disease.

Johnson & Johnson (NYSE:JNJ) was discussed in the Q2 2022 investor letter of Distillate Capital Partners LLC. Here’s what the firm said:

“Johnson & Johnson was among the 2 largest trims at around 1% each. Each stock was up 1% in the quarter compared to the 16% price decline for the S&P 500 and the positions were reduced as the valuations became somewhat less appealing, though still attractive enough to warrant inclusion.”

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on the 10 Best Small-Cap Growth Stocks to Buy Now and the 20 Largest R&D Companies in the World.